Given that patients with HER2-expressing breast cancers also have a poorer relative prognosis, particularly when their cancers are initially resistant or acquire resistance to the HER2 targeting agent trastuzumab [14], investigation of the potential benefit for blocking the protumorigenic effects of TMEPAI in this cancer subtype may also be warranted. The gene discussed is ERBB2; the disease is breast carcinoma.